GlobeNewsWire
21 Jul 2026, 11:50 UTC · 8w ago
Verdict
Headline takes no side. We score HELP +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Helus Pharma completed enrollment for the Phase 3 APPROACH study of HLP003 ahead of schedule.
More positive than 76% of claims this week
Topline data for the APPROACH study is expected to be released in Q4 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 62% of claims this week
The company targets a potential FDA New Drug Application (NDA) for HLP003 in 2028.
More positive than 49% of claims this week
HLP003 has previously received Breakthrough Therapy Designation from the FDA.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company completed its Phase 3 study enrollment ahead of schedule and reported strong previous Phase 2 efficacy data.
More positive than 58% of ticker scores this week
The company reported significant year-over-year and quarter-over-quarter sales growth for its drug SPRAVATO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3d ago
+74.0%
Price agrees with the score
$12.37 vs $7.11 close before publication (Jul 20) · not market-adjusted
HELP chart →
